Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 1997 Jul;67(7):400-9.
doi: 10.1111/j.1445-2197.1997.tb02003.x.

The aetiology and management of hepatic metastases

Affiliations
Review

The aetiology and management of hepatic metastases

T J Hugh et al. Aust N Z J Surg. 1997 Jul.

Abstract

Hepatic metastases are a common event in the metastatic spread of primary tumours and indicate advanced disease. However, the presence of hepatic metastases does not necessarily imply incurability; in selected patients resection of hepatic metastases may result in 5-year survival rates of 25-35%, usually in patients with colorectal liver metastases in whom solitary metastases are more frequent than with other primary tumours. However, hepatic metastases from Wilm's tumours, adrenal tumours, renal cell carcinoma, and neuroendocrine tumours may also be resected with similar success rates. A poor prognosis after resection of hepatic metastases is likely when there are more than three metastatic deposits, involved resection margins (often as a result of 'wedge' resections), when there is extrahepatic disease, or nodal involvement at the primary tumour site. Cyto-reductive procedures may provide excellent palliation and possibly long-term survival in selected patients with hepatic metastases unsuitable for resection. However, further study is required to establish the appropriate role for these treatments.

PubMed Disclaimer

Similar articles

Cited by

  • Microwave coagulation for liver metastases.
    Storman D, Swierz MJ, Mitus JW, Pedziwiatr M, Liang N, Wolff R, Bala MM. Storman D, et al. Cochrane Database Syst Rev. 2024 Mar 27;3(3):CD010163. doi: 10.1002/14651858.CD010163.pub3. Cochrane Database Syst Rev. 2024. PMID: 38534000 Free PMC article. Review.
  • Percutaneous ethanol injection for liver metastases.
    Swierz MJ, Storman D, Riemsma RP, Wolff R, Mitus JW, Pedziwiatr M, Kleijnen J, Bala MM. Swierz MJ, et al. Cochrane Database Syst Rev. 2020 Feb 4;2(2):CD008717. doi: 10.1002/14651858.CD008717.pub3. Cochrane Database Syst Rev. 2020. PMID: 32017845 Free PMC article.
  • Transarterial (chemo)embolisation versus no intervention or placebo for liver metastases.
    Swierz MJ, Storman D, Riemsma RP, Wolff R, Mitus JW, Pedziwiatr M, Kleijnen J, Bala MM. Swierz MJ, et al. Cochrane Database Syst Rev. 2020 Mar 12;3(3):CD009498. doi: 10.1002/14651858.CD009498.pub4. Cochrane Database Syst Rev. 2020. PMID: 32163181 Free PMC article.
  • Cryotherapy for liver metastases.
    Bala MM, Riemsma RP, Wolff R, Pedziwiatr M, Mitus JW, Storman D, Swierz MJ, Kleijnen J. Bala MM, et al. Cochrane Database Syst Rev. 2019 Jul 10;7(7):CD009058. doi: 10.1002/14651858.CD009058.pub3. Cochrane Database Syst Rev. 2019. PMID: 31291464 Free PMC article.

Publication types

LinkOut - more resources